Smartlens is a clinical-stage company with a portfolio of technologies to treat and diagnose glaucoma - a chronic, incurable eye disease as the leading cause of irreversible blindness. Smartlens has developed a unique platform that enables early diagnosis and helps prevent disease progression. It significantly improves the efficacy of treatments and paves the way for a new generation of therapies. The Company’s miLens is a novel contact lens-based device, capable of monitoring intraocular pressure (the primary and only treatable risk factor of glaucoma) thus addressing a big unmet need since the 1950s. The disease affects hundreds of millions around the globe; even in developed countries, more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. Monitoring eye pressure has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology to help improve clinical outcomes. miLens utilizes a novel, electronics-free sensor technology owned by Smartlens and protected by a portfolio of issued and pending patents covering more than 40 countries. Its technology is also being studied at Stanford University to monitor ICP associated with certain neurological disorders and cancers. Smartlens also owns THERmic, a next-generation, non-invasive, and adaptive drug delivery technology that monitors efficacy and applies personalized therapies for each patient. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. At Smartlens, we envision a world where Glaucoma can’t rob people of their vision and quality of life.